8-K: Liminatus Pharma Faces Nasdaq Delisting Risk

Liminatus Pharma received a notice from Nasdaq indicating it has not regained compliance with the minimum bid price rule and is not eligible for a second extension, with a decision on continued listing pending.

Summary

• Liminatus Pharma, Inc. received a notice from Nasdaq on July 20, 2026, stating it has not met the minimum bid price requirement of $1 per share for 30 consecutive business days.
• The company was previously notified of this deficiency on January 15, 2026, and had a 180-day compliance period until July 14, 2026.
• A hearing was held on June 30, 2026, where the company requested an extension, but Nasdaq has indicated it is not eligible for a second 180-day extension.
• Liminatus Pharma plans to submit a written response to the Nasdaq Hearings Panel by July 27, 2026, to present its views on the deficiency.
• There is no assurance that the Panel will grant additional time or that the company will regain compliance.
• The company also filed a definitive proxy statement on July 13, 2026, for an August 3, 2026, annual meeting to seek authorization for a reverse stock split.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the direct threat of delisting from Nasdaq and the company's ineligibility for further extensions, despite plans to respond to the panel.

Negatives

• The company has failed to regain compliance with Nasdaq's minimum bid price rule ($1.00).
• Liminatus Pharma is not eligible for a second 180-day extension to regain compliance.
• The Nasdaq Hearings Panel will consider the deficiency in their decision regarding the company's continued listing on Nasdaq.

Risks

• Potential delisting from The Nasdaq Stock Market LLC if the company cannot regain compliance with listing rules.
• The company may not be granted additional time by the Nasdaq Hearings Panel to come back into compliance.
• Actual actions or events could differ materially from forward-looking statements, impacting the company's ability to meet listing standards.

Future Outlook

The company plans to submit a written response to the Nasdaq Hearings Panel by July 27, 2026, to present its views on the deficiency. There can be no assurance that the Panel will grant additional time or that the company will be able to regain compliance with the Minimum Bid Price Rule or meet Nasdaq's continued listing standards.

Management Comments

• The Company plans to submit a timely written response to the Panel regarding the additional deficiency.

Industry Context

StockSavvy.ai notes that continued non-compliance with minimum bid price rules and the subsequent risk of delisting are critical concerns for small-cap and micro-cap companies, particularly in the biotechnology and pharmaceutical sectors where funding and market sentiment can be volatile.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased risk of delisting, potential dilution if a reverse stock split is approved, and uncertainty regarding future stock performance.
• Creditors: Potential impact on the company's ability to service debt if delisting leads to financial distress.
• Employees: Job security may be impacted by potential delisting and financial instability.

Next Steps

• Submit a written response to the Nasdaq Hearings Panel by July 27, 2026.
• Await the Nasdaq Hearings Panel's decision regarding the company's continued listing.
• Hold annual meeting of stockholders on August 3, 2026, to vote on proposals including a reverse stock split.

Key Dates

Recommendation

While the immediate threat of delisting is significant, the company is actively engaging with Nasdaq and has a plan to address the deficiency, including a potential reverse stock split. A 'hold' recommendation reflects the uncertainty and the need to await the outcome of the Nasdaq panel's decision and the stockholder vote on the reverse split.

Keywords

Nasdaq Delisting, Bid Price Rule, Reverse Stock Split, Listing Compliance, SEC Filing, Liminatus Pharma, Proxy Statement, Annual Meeting